PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35459869-0	2022	AGR2-induced cholesterol synthesis drives lovastatin resistance that is overcome by combination therapy with allicin.	Lovastatin	42-52	anterior gradient 2	Mus musculus	0-4	
35459869-6	2022	Moreover, elevated AGR2 led to a significant decrease in the lipid-lowering efficacy of lovastatin (10 mg  kg-1  d-1, ip, for 2 weeks) in mice with hypercholesterolemia (hyperCho), which was validated by results obtained from clinical samples in statin-treated patients.	Lovastatin	88-98	anterior gradient 2	Mus musculus	19-23	
35459869-9	2022	Importantly, the AGR2-reduced lipid-lowering efficacy of lovastatin was attenuated, at least partially, by co-administration of a sulfhydryl-reactive compound allicin (20 mg  kg-1  d-1, ip, for 2 weeks).	Lovastatin	57-67	anterior gradient 2	Mus musculus	17-21